OncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in Stock

OncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs purchased 3,390 shares of OncoCyte stock in a transaction on Thursday, April 11th. The shares were acquired at an average cost of $2.95 per share, for a total transaction of $10,000.50. Following the purchase, the chief executive officer now owns 3,505 shares in the company, valued at $10,339.75. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

OncoCyte Stock Performance

OCX stock opened at $2.53 on Tuesday. The business has a fifty day simple moving average of $2.96 and a 200-day simple moving average of $3.06. OncoCyte Co. has a 52 week low of $2.08 and a 52 week high of $6.80.

Institutional Trading of OncoCyte

A number of institutional investors and hedge funds have recently made changes to their positions in OCX. Millennium Management LLC acquired a new stake in shares of OncoCyte during the 2nd quarter worth $896,000. Geode Capital Management LLC increased its holdings in shares of OncoCyte by 23.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,228,553 shares of the company’s stock worth $283,000 after buying an additional 236,099 shares during the last quarter. Vanguard Group Inc. increased its holdings in OncoCyte by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 3,986,270 shares of the company’s stock valued at $5,940,000 after purchasing an additional 90,534 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in OncoCyte by 17.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 541,983 shares of the company’s stock valued at $487,000 after purchasing an additional 81,979 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in OncoCyte by 131.7% in the 2nd quarter. Renaissance Technologies LLC now owns 138,100 shares of the company’s stock valued at $32,000 after purchasing an additional 78,500 shares in the last quarter. 55.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on OCX. StockNews.com began coverage on OncoCyte in a research note on Friday. They set a “sell” rating on the stock. Benchmark reissued a “speculative buy” rating and set a $5.00 price target on shares of OncoCyte in a research note on Monday.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.